Loading data
CLDINYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | 45 k USD |
| Research and development expense | 9.74 m USD | 8.88 m USD | 13.01 m USD | 7.26 m USD |
| Selling, general and administrative expense | 10.5 m USD | 12.9 m USD | 15.98 m USD | 15.9 m USD |
| Operating profit | -20.24 m USD | -21.78 m USD | -28.99 m USD | -23.13 m USD |
| Profit before tax | -20.05 m USD | -22.2 m USD | -29.2 m USD | -25.42 m USD |
| Income tax expense | 15 k USD | 14 k USD | 16 k USD | 11 k USD |
| Net income (reported basis) | -19.91 m USD | -22.14 m USD | -29.22 m USD | -25.43 m USD |
| Net income attributable to common shareholders | -25.58 m USD | -23.81 m USD | -29.22 m USD | 1.07 m USD |
| Basic earnings per share | -5.95 USD/share | -35.7 USD/share | -207.62 USD/share | 2.99 USD/share |
| Diluted earnings per share | -5.95 USD/share | -35.7 USD/share | -207.62 USD/share | 29.9 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.